截至发稿，陈印累计任职时间200天，现任基金资产总规模1645.45万元，任职期间最佳基金回报 34.61%， 任职期间最差基金回报34.28%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，淳厚基金旗下1只基金重仓英科医疗。淳厚时代优选混合A（014235）四季度持有股数1.2万 股，与上期相比持股数量不变，占基金净值比例为2.84%，位居第四大重仓股。根据测算，今日浮亏损 失约3.11万元。 淳厚时代优选混合A（014235）成立日期2022年1月27日，最新规模1464.72万。今年以来收益6.65%， 同类排名3570/8861；近一年收益39.41%，同类排名3052/8126；成立以来收益2.31%。 淳厚时代优 ...

Core Viewpoint - In recent trading, Yingke Medical experienced a decline of 2.17% with a transaction volume of 517 million yuan, indicating a negative sentiment in the market [1] Financing and Margin Trading - On January 16, Yingke Medical had a financing buy amount of 47.01 million yuan and a financing repayment of 65.46 million yuan, resulting in a net financing outflow of 18.45 million yuan [1] - The total margin trading balance for Yingke Medical as of January 16 is 571 million yuan, with a financing balance of 559 million yuan, representing 2.10% of the circulating market value, which is below the 20th percentile level over the past year [1] - In terms of securities lending, 3,500 shares were repaid and 8,400 shares were sold on January 16, with a selling amount of 348,500 yuan, while the securities lending balance is 11.55 million yuan, exceeding the 80th percentile level over the past year [1] Financial Performance - For the period from January to September 2025, Yingke Medical achieved an operating income of 7.425 billion yuan, reflecting a year-on-year growth of 4.60%, and a net profit attributable to shareholders of 924 million yuan, which is a 34.47% increase year-on-year [2] Shareholder Information - As of September 30, 2025, Yingke Medical had 47,300 shareholders, a decrease of 21.11% from the previous period, while the average number of circulating shares per person increased by 25.65% to 9,832 shares [2] - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with some shareholders reducing their holdings while others increased or newly entered [4] Dividend Distribution - Yingke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]

Group 1 - In December 26, 2023, Yingke Medical's stock price fell by 5.04%, closing at 41.28 yuan per share, with a trading volume of 431 million yuan and a turnover rate of 2.20%. The total market capitalization is 27.045 billion yuan. The stock has experienced a consecutive decline over three days, with a cumulative drop of 2.05% during this period [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009. The company went public on July 21, 2017. Its main business includes three segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major holdings, one fund under Zhongyou Fund holds a significant position in Yingke Medical. The Zhongyou Strategic Emerging Industries Mixed A Fund (590008) held 1 million shares in the third quarter, accounting for 4.09% of the fund's net value, ranking as the ninth largest holding. The estimated floating loss today is approximately 2.19 million yuan, with a floating loss of 910,000 yuan during the three-day decline [2] - The Zhongyou Strategic Emerging Industries Mixed A Fund (590008) was established on June 12, 2012, with a current scale of 888 million yuan. Year-to-date returns are 30.77%, ranking 3055 out of 8087 in its category; the one-year return is 30.59%, ranking 2900 out of 8074; and since inception, the return is 560% [2]

Core Viewpoint - The company, Jiangsu Lude Medical Electronics Co., Ltd., is focused on innovation in technology and lean manufacturing, aiming to build a comprehensive family health ecosystem through a dual-driven strategy of "medical devices + health management" [1][2]. Group 1: Shareholder Activity - The company's major shareholder, Dong Shixiang, has reduced his holdings by 2.48 million shares, representing a decrease of 1.4212%, with a total reduction amounting to 23.92 million yuan, leaving him with 7.7584 million shares, which is 4.4461% of the total shares [1]. Group 2: Product and Market Strategy - The company has developed a complete industrial chain from product research and development to global sales, focusing on home medical devices and health care products, including cardiovascular monitoring and respiratory therapy [1]. - The company is actively engaged in the "smart elderly care + home health care" sector, providing health management solutions for the elderly through smart wearable devices that monitor vital signs [2]. - Sales are primarily concentrated in overseas markets, utilizing an ODM model and establishing strong partnerships with local brands through participation in international medical device exhibitions [2]. - The company is expanding its reach through cross-border e-commerce platforms like Amazon and Alibaba, directly accessing end consumers [2]. Group 3: Operational Efficiency - The company is implementing lean management practices to optimize production line layouts and improve capacity utilization, thereby enhancing production efficiency [2]. - It prioritizes resource allocation for important clients and short delivery cycle orders to ensure product delivery capabilities [2]. - The construction of the Lude Medical Health Industrial Park is underway, with the first phase expected to be completed next year, aimed at improving R&D efficiency and reducing innovation costs [2]. Group 4: Marketing and R&D - The company is actively participating in industry exhibitions and client visits to expand its customer base and strengthen communication with major clients [3]. - There has been a year-on-year increase in new foreign trade customers and sales through cross-border e-commerce platforms [3]. - The company continues to enhance its product innovation and accelerate product registration and certification, with a focus on new applications for nebulization [3]. - As of June 2025, the company holds 113 authorized patents, including 9 invention patents, providing substantial technical support for its ongoing operations [3]. Group 5: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 216 million yuan and a net profit attributable to shareholders of 17.69 million yuan [4].

Group 1 - The core viewpoint of the news is that Yingke Medical has seen a 5% increase in stock price, reaching 40.50 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 26.519 billion CNY [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major fund holdings, one fund under the Fortune Fund has a significant position in Yingke Medical. The Fortune CSI Pharmaceutical Theme Index Enhanced Fund (LOF) A (161035) held 193,700 shares in the third quarter, accounting for 1.79% of the fund's net value, ranking as the ninth largest holding. The estimated floating profit today is approximately 373,800 CNY [2] - The Fortune CSI Pharmaceutical Theme Index Enhanced Fund (LOF) A (161035) was established on November 11, 2016, with a current scale of 353 million CNY. Year-to-date returns are 15.91%, ranking 2658 out of 4208 in its category; the one-year return is 10.07%, ranking 2920 out of 3981; and since inception, the return is 41.07% [2] Group 3 - The fund managers of the Fortune CSI Pharmaceutical Theme Index Enhanced Fund (LOF) A (161035) are Niu Zhidong and Cai Kaer. As of the report, Niu Zhidong has a tenure of 10 years and 199 days, managing assets totaling 24.849 billion CNY, with the best fund return during his tenure being 111.51% and the worst being -88.81%. Cai Kaer has a tenure of 8 years and 325 days, managing assets totaling 111.894 billion CNY, with the best return of 51.06% and the worst of -32.1% [3]

Core Viewpoint - Inco Medical experienced a decline of 5.05% in its stock price, reaching 37.42 CNY per share, with a trading volume of 321 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 24.502 billion CNY [1] Company Overview - Inco Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017 [1] - The company's main business segments include personal protection, rehabilitation care, and other products, with revenue composition as follows: personal protection 91.47%, rehabilitation care 4.75%, and other products 3.77% [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Caitong Fund has a significant position in Inco Medical [2] - Caitong Medical Health Mixed A Fund (018937) held 95,200 shares in the third quarter, accounting for 5.97% of the fund's net value, making it the second-largest holding [2] - The fund has experienced a floating loss of approximately 189,400 CNY today [2] Fund Performance - Caitong Medical Health Mixed A Fund (018937) was established on March 27, 2024, with a latest scale of 50.4705 million CNY [2] - Year-to-date return is 14.86%, ranking 5206 out of 8213 in its category; the one-year return is 13.41%, ranking 5016 out of 8130; and since inception, the return is 14.15% [2] - The fund manager, Luo Ying, has a tenure of 4 years and 130 days, with total assets under management of 58.5742 million CNY [2]

Core Viewpoint - Inke Medical's stock price has shown significant growth this year, with a year-to-date increase of 64.94%, reflecting strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Inke Medical reported a revenue of 7.425 billion yuan, representing a year-on-year growth of 4.60% [2]. - The net profit attributable to shareholders for the same period was 924 million yuan, marking a substantial increase of 34.47% compared to the previous year [2]. Stock Market Activity - As of November 12, Inke Medical's stock price reached 41.45 yuan per share, with a trading volume of 230 million yuan and a market capitalization of 27.141 billion yuan [1]. - The stock experienced a net inflow of 15.9098 million yuan from institutional investors, indicating positive sentiment [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Inke Medical decreased by 21.11% to 47,300, while the average number of shares held per shareholder increased by 25.65% to 9,832 shares [2][4]. - The top circulating shareholders include various ETFs and mutual funds, with notable changes in holdings among major investors [4]. Dividend Distribution - Inke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3].

Core Viewpoint - In recent trading, Yingke Medical's stock price has shown a decline of 2.02%, with a current price of 38.36 CNY per share and a total market capitalization of 25.118 billion CNY. The company has experienced a year-to-date stock price increase of 52.64% [1] Financial Performance - For the period from January to September 2025, Yingke Medical reported a revenue of 7.425 billion CNY, reflecting a year-on-year growth of 4.60%. The net profit attributable to shareholders was 924 million CNY, marking a significant increase of 34.47% compared to the previous year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Yingke Medical decreased by 21.11% to 47,300. The average number of circulating shares per shareholder increased by 25.65% to 9,832 shares [2] Dividend Distribution - Yingke Medical has cumulatively distributed dividends amounting to 1.903 billion CNY since its A-share listing, with a total of 245 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Yingke Medical include notable ETFs such as Huabao Zhongzheng Medical ETF and Yifangda Growth Enterprise Board ETF, with some shareholders reducing their holdings while others have newly entered [4]

Group 1 - The core viewpoint of the news is that Yingke Medical's stock has increased by 5.01%, reaching a price of 42.13 CNY per share, with a trading volume of 565 million CNY and a turnover rate of 2.95%, resulting in a total market capitalization of 27.586 billion CNY [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company operates in three main business segments: personal protection, rehabilitation care, and other products [1] - The revenue composition of Yingke Medical is as follows: personal protection accounts for 91.47%, rehabilitation care for 4.75%, and other products for 3.77% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund ranks among the top shareholders of Yingke Medical. The Southern CSI 500 ETF (510500) increased its holdings by 967,200 shares in the second quarter, bringing its total to 6.698 million shares, which represents 1.43% of the circulating shares [2] - The estimated floating profit for the Southern CSI 500 ETF today is approximately 13.4629 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion CNY. Year-to-date returns are 28.62%, ranking 1823 out of 4219 in its category, while the one-year return is 28.52%, ranking 1678 out of 3877 [2]

Group 1 - The core point of the news is that Yingke Medical's stock price increased by 5.01% to 42.13 CNY per share, with a trading volume of 566 million CNY and a turnover rate of 2.96%, resulting in a total market capitalization of 27.586 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - According to data from fund holdings, one fund under Zheshang Securities Asset Management heavily invests in Yingke Medical, with Zheshang Huijin Quantitative Selected Stocks A (011824) holding 40,200 shares, accounting for 0.75% of the fund's net value, making it the second-largest holding [2] - The fund has achieved a year-to-date return of 27.54%, ranking 1932 out of 4219 in its category, and a one-year return of 32.66%, ranking 1391 out of 3877 [2] Group 3 - The fund manager of Zheshang Huijin Quantitative Selected Stocks A is Chen Gujun, who has been in the position for 5 years and 282 days, with the fund's total asset size at 204 million CNY [3] - During Chen Gujun's tenure, the best fund return was 38.13%, while the worst was -7.57% [3]